ARDAT overview

Working towards
safe and effective
Advanced Therapy
Medicinal Products

Project fact sheet


Accelerating Research & Development for Advanced Therapies

Expanding the knowledge on advanced therapies

Curative or near curative therapies for Rare and Orphan Diseases have been a long-held desire for both patients and many in the biomedical research and development area. Rare diseases are often very severe, genetically driven illnesses with high morbidity and mortality that place a large burden on families of patients and healthcare systems. Though these diseases are relatively rare the costs of medicines are high, even for the many that provide only marginal benefit. Gene and cell therapies provide an opportunity for a curative, single treatment for many of these devastating diseases, eliminating the need for chronic treatment.

> 0
rare diseases

Our Expertise

The  ARDAT (Accelerating Research & Development for Advanced Therapies) project is founded on an international consortium of participants with  compelling track records in the field of advanced therapies to create a ‘best-with-best’ multidisciplinary team of  leading academic and EFPIA groups with complementary expertise in:

  • Gene therapy
  • Immunology
  • Chemistry
  • Engineering
  • Biotechnology
  • Drug safety
  • Viral vector production
  • Regulatory and clinical trials
Looking for more information

Explore Our Project

Work packages

The project consists of several research groups, each responsible for key parts of the work plan


The consortium has members from across the established pharmaceutical industry, small/medium sized businesses and academia


Read all about our recent advancements and activities as we engage with patient groups and regulators


We are planning to publish our results through several articles in scientific peer reviewed journals

months interval
consortium members